Clinical Trials
6 trialsNCT04624204 2026-05-26
MK 7339-013
Merck Sharp & Dohme LLC
Phase 3 Active not recruiting
NCT06128148 2025-07-14
JYP0322
Guangzhou JOYO Pharma Co., Ltd
Phase 1 Recruiting
NCT04820023 2025-06-06
Phase 1/2 Study of BBT-176 in Advanced NSCLC With Progression After EGFR TKI Treatment
Bridge Biotherapeutics, Inc.
Phase 1/2 Terminated
NCT06082635 2025-05-18
TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)
Shenzhen TargetRx Co., Ltd.
Phase 3 Active not recruiting
NCT04515979 2024-12-09
Vactosertib in Combination with Pembrolizumab for PD-L1 Positive Non-small Cell Lung Cancer (NSCLC) Subjects
MedPacto, Inc.
Phase 2 Terminated
NCT01976741 2021-05-06
Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)
Bayer
Phase 1 Completed